
1. expert rev vaccines. 2008 sep;7(7):915-23. doi: 10.1586/14760584.7.7.915.

immunotherapy hcv infection: next steps.

lang k(1), weiner db.

author information: 
(1)department pathology laboratory medicine, university pennsylvania,
philadelphia, pa 19104-6100, usa. krystlea@mail.med.upenn.edu

with 170 million individuals currently infected, hcv global
pandemic, effecting approximately 3% entire world's population. hcv
infection growing infectious disease pandemic approximately 3-4 million
new cases reported year. due persistent nature virus, 70-90%
of infected individuals develop chronic infection, lead to
progressive liver disease including cirrhosis hepatocellular carcinoma.
current standard treatment combination ifn-alpha ribavirin has
improved prognosis many hcv sufferers; however, infection very
difficult treat successfully protocol treatment neither simple,
well tolerated economically favorable. standard treatment cost average
of us$22,000, depending genotype, 42% treated individuals
will clear infection. collection treatment issues combined new
concepts immune therapy serve underscore urgent need development
of improved immunotherapies, novel interferons, support possible 
development therapeutic vaccines treatment chronic hcv infection.

doi: 10.1586/14760584.7.7.915 
pmid: 18767942  [indexed medline]

